SOAT1 and type 2 diabetes mellitus: To assess this, we used JAK1/2-selective inhibitor ruxolitinib to assess the sensitivity of mROS production in HSVSMCs from non-diabetic and T2DM patients in response to inhibition of the JAK/STAT pathway.